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Abstract 
A Paediatric Investigation Plan (PIP) is a development plan that aims to ensure that 
sufficient data are obtained through studies in paediatrics to support the generation of 
marketing authorisation of medicines for children. This paper highlights some 
practical considerations and challenges with respect to PIP submissions and paediatric 
clinical trials during the pharmaceutical development phase, using the FP7-funded 
Clonidine for Sedation of Paediatric Patients in the Intensive Care Unit (CloSed) 
project as a case study. Examples discussed include challenges and considerations 
regarding formulation development, blinding and randomisation, product labelling 
and shipment and clinical trial requirements versus requirements for marketing 
authorisation. A significant quantity of information is required for PIP submissions 
and it is hoped that future applicants may benefit from an insight into some critical 
considerations and challenges faced in the CloSed project. 
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1 Introduction 
Children under the age of 15 represent 16% of the total European population 
(Eurostat, 2015; Population Reference Bureau, 2013). However, a survey published in 
2010 by the European Medicines Agency (EMA) found that 45-60% of all medicines 
given to children in the European Union (EU) were used off-label, especially in 
vulnerable groups such as neonates, patients with serious conditions and those in 
intensive care units (EMA, 2010). Off-label medicine usage refers to a medicine 
prescribed outside of its marketing authorisation. Reasons for the lack of availability 
and marketing authorisation for medicines for children include a scarcity of clinical 
trials in paediatric medicines, delays in the licensing of medicines for children, the 
absence of child-friendly formulations and a lack of commercial incentive (Ivanovska 
et al., 2013). In 2007, the EU introduced Regulation (EC) No. 1901/2006 of the 
European Parliament and of the Council on medicinal products for paediatric use as 
amended (Paediatric Regulation) to improve the health of children up to the age of 18 
by supporting the development and accessibility of paediatric medicines and 
improving data available regarding their use. In doing so, the long-term goal was to 
achieve an integrated approach to the development of paediatric medicines within 
medicines development in general without unnecessary studies in children and 
without delaying marketing authorisations for medicines intended for use in adults. 
The Paediatric Regulation encourages pharmaceutical manufacturers to investigate 
drug development for the paediatric population by providing a Paediatric 
Investigation Plan (PIP) prior to marketing authorisation of new drugs. Incentives 
such as the extension of supplementary protection certificate (SPC) or a Paediatric 
Use Marketing Authorisation (PUMA) (for off-patent drugs) are provided if a 
previously agreed PIP is successfully completed. Whereas the Paediatric Regulation 
has been successful for new drugs, off-patent drugs are rarely studied. This is shown 
by the fact that only two PUMAs for off-patent drugs have been granted between 
2008 and 2015 (EMA, 2015; Turner et al., 2014). In order to address this, the EMA 
developed a priority list of studies into off-patent paediatric medicines to serve as a 
platform for EU research funding.  
 3 
 
The purpose of this paper is to highlight some considerations and challenges with 
respect to PIP submissions and the implementation of paediatric clinical trials during 
the pharmaceutical development phase, using the FP7-funded Clonidine for Sedation 
of Paediatric Patients in the Intensive Care Unit (CloSed) project as a case study. A 
positive PIP opinion at the time of application was considered fundamental in 
supporting this funding proposal. At the time of PIP submission a significant amount 
of information is required, however the practical implementation of this plan may 
result in some challenges. Therefore, it is hoped that future applicants may benefit 
from an insight into some critical considerations and challenges faced in the CloSed 
project. 
 
2 Clonidine and the CloSed project 
The CloSed project is a five-year EU funded project (EudraCT: 2014-003582-24) 
that aims to generate data for a PUMA application in accordance with the Paediatric 
Regulation by developing an age-appropriate intravenous clonidine formulation and 
conducting a multicentre clinical trial of clonidine for the sedation of children aged 0-
18 years in a Paediatric Intensive Care Unit (PICU) setting (see ClinicalTrials.gov, 
ref. NCT02509273). At the time of this publication, patient recruitment and data 
collection of the clinical trial was commencing. Although clonidine is used for 
sedation in many PICUs, it lacks authorisation for paediatric use. Clonidine was 
therefore included in the EMA Revised Priority List for Studies into Off-Patent 
Paediatric Medicinal Products July 2012 (EMA/98717/2012), which highlighted a 
need for paediatric data relating to pharmacokinetics, efficacy and safety and age-
appropriate formulations for clonidine in the treatment of pain and sedation in PICUs 
(EMA, 2013). Prior to the funding application a PIP with a comprehensive 
development plan for clonidine was developed and agreed with EMA. The CloSed 
project has several concrete objectives, as outlined in Table 1. While these outcomes 
are specific to the CloSed project, they could be applied to any paediatric clinical trial. 
Further information on the CloSed project can be obtained from the official project 
website (http://www.closed-fp7.eu). 
 
There are many challenges involved in developing and conducting a clinical trial, 
particularly in children and the CloSed project has been no exception. In the following 
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sections challenges and considerations regarding formulation development, blinding 
and randomisation, product labelling and shipment and clinical trial requirements 
versus PUMA requirements are discussed in detail. 
 
Table 1 Summary of concrete outcomes expected from the CloSed project. 
Development of an age-appropriate IV formulation of clonidine 
 This will allow accurate dosing with minimum risk for errors. 
Safety/efficacy data for clonidine in children 
 Evidence-based data on the safety, efficacy and dosing recommendation for 
the use of clonidine for sedation of children in PICU. 
Long-term neurodevelopmental outcomes 
 An understanding of long-term outcomes following the sedative agents 
clonidine and midazolam in neonates will help in the assessment of risks and 
benefits for treatment.  
Paediatric Use Marketing Authorisation (PUMA) 
 Data will be used to apply for a PUMA for the age-appropriate IV clonidine 
formulation to facilitate the availability of a licensed product designed for use 
in PICUs. 
European consensus guidelines 
 International guidelines will be prepared based on the study results to address 
the lack of European guidelines and current low evidence to support 
treatment options. Clinical practice may be improved by the dissemination of 
results to a wide range of health professionals. 
Extension of the availability of paediatric medicines to benefit children 
 An estimated 120,000 critically ill children per year will benefit from a 
licensed clonidine product for sedation in PICUs and consensus guidelines 
for sedation. 
Promotion of research in children 
 CloSed Partners are encouraged to participate in clinical trials beyond CloSed 
and extend their knowledge and experience in conducting clinical research in 
the vulnerable paediatric population. 
Innovation by strengthening links between academia and industry 
 CloSed brings academic expertise together, using modern methods such as 
PK-PD modelling to define the best study design in an ethical manner.  
Assuming that the PUMA is granted, the developed formulation will be 
marketed, increasing the availability and providing synergism between 
scientific and market knowledge. 
 
3.1 Formulation development 
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In the development of an age-appropriate formulation for paediatric patients including 
premature neonates right through to adolescents, selected strengths, volumes and 
excipients require careful consideration. In addition to the broad age range, dosing 
needs to be flexible in order to be adjusted based on individual patient requirements. 
The focus of the CloSed project is on the development of an age-appropriate 
parenteral clonidine formulation that may be used for the sedation of paediatric 
patients from premature neonates (>34 weeks gestation) right through to adolescents 
up to 18 years old. Currently, commercial IV clonidine formulations licensed for the 
treatment of hypertension in adults, such as Catapres® 150 mcg/mL (Boehringer 
Ingelheim, Berkshire, UK), are used for the sedation of children in PICU. This 
product is manufactured in 1 mL ampoules and anecdotal evidence indicates that up 
to 20 ampoules need to be opened and mixed to provide accurate dose-volume 
administration. The use of multiple ampoules is particularly prone to administration 
errors, inappropriate dosing and requires additional clinical or nursing time (WHO, 
2007; Wong et al., 2009). It was important in the pharmaceutical development of the 
CloSed study that a minimal number of strengths were used to cover the entire age 
range in order for successful translation from investigational medicinal product (IMP) 
to final marketed product.  
 
Before the formulation strengths can be selected, the dosing regimen must be 
established. Pharmacokinetic-pharmacodynamic (PK-PD) modelling was used in the 
CloSed study to determine the most appropriate starting and maintenance doses for 
critically ill children admitted to PICU. In addition, different dosing scenarios were 
considered to ensure that blinding could be maintained between the clonidine and 
midazolam arms. Although this was not part of the pharmaceutical development itself, 
it was a critical step in the determination of formulation strengths and excipients. In 
order to develop a formulation of appropriate strength(s), the dosing regimen requires 
careful consideration as this dictates both the concentration and volume to be 
administered to patients. In the CloSed study, midazolam was used as a comparator to 
clonidine and in order to maintain blinding, the dosing regimen for both IMPs needed 
to be the same. However, the elimination half-life of clonidine is long (9-17 hours) 
compared with that of midazolam (1-3 hours, increasing up to 12 hours in neonates) 
and this was an important consideration when developing a dosing regimen. A 
marketed product of midazolam is available at concentrations of 1mg/mL and 
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5mg/mL, which are appropriate for paediatric sedation (European Commission, 
2014). However, it was not possible to maintain blinding by matching the dosing 
regimen and physical characteristics of the vials with clonidine using this product, so 
midazolam was also manufactured specifically for use as a comparator in this study. 
 
The selection of excipients for each formulation was based on the marketed products 
Catapres® (clonidine, Boehringer Ingelheim, Berkshire, UK) and Hypnovel® 
(midazolam, Roche, Hertfordshire, UK). Both formulations were prepared in 
0.9% v/v sodium chloride as the diluent (European Commission, 2014). The solubility 
of clonidine HCl in water is 77mg/mL at 20°C (O'Neil, 2013), whereas the solubility 
of midazolam decreases with increasing pH (10.3mg/mL at pH 3.4 compared to 0.24 
mg/mL at pH 6.2). The final products were modified to pH 4.8-6.5 for clonidine HCl 
and pH 3.0-3.7 for midazolam, according to the stability profile of the drug 
substance (American Society of Health-System Pharmacists, 2015). No preservative 
was required, as a single-use product was desired.  
 
Administration by continuous intravenous infusion allows for flexible dosing, but it is 
important to consider the minimal flow rate of infusion pumps. To this end, a 
preliminary audit was conducted to determine the pump capacity at each of the 
clinical sites involved in the study. The basic fluid requirement for a term baby is 
between 40 and 60 mL/kg/day plus urinary losses (BMJ Group, 2011). Neonates, 
particularly if fluid restricted, may tolerate only small volumes of medication to avoid 
fluid overload and allow sufficient room for fluid nutrition. In addition, in a paediatric 
intensive care setting it is common for several intravenous drugs to be required, which 
require dilution and flushing into the circulation. This could result in the child’s fluid 
and sodium requirements being exceeded. According to the BNF for children, the 
sodium requirement in most healthy neonates is 3.0mmol/kg/day (BMJ Group, 2011), 
with UK guidelines recommending a maximum of 400mg (17.4mmol) sodium per day 
in children up to the age of 12 months (Scientific Advisory Committee on Nutrition, 
2003). The maximum sodium intake for each formulation, calculated based on a 
patient requiring the maximum dose over 24 hours, was considered satisfactory as it 
was less than 30% of this recommended threshold.  
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After considering the above factors, three strengths were developed, each at a volume 
of 50mL. A 50mL volume was selected because even if a patient required the 
maximum dosage in 24 hours, one vial would be required unless the patient was over 
47kg, where two vials may be required. The three strengths allowed infusion rates to 
remain greater than the minimal flow rate of the infusion pumps for all age groups at 
all clinical sites, whilst maintaining a low fluid volume to avoid fluid overload. 
 
3.2 Blinding and randomisation 
3.2.1 Blinding 
The CloSed study, like many other clinical trials, is a double-blinded trial, so neither 
the principal investigator (and associated study site staff) nor the patient (and patient’s 
family) are aware of the specific treatment allocation. PK-PD modelling played a 
large part in the ability to blind the reference and test product vials, by developing a 
matched dosing regimen. As previously discussed, the half-life of clonidine is much 
longer than of midazolam, so this had to be considered in order to maintain a blinded 
dosing regimen. To achieve this, an initial loading dose was proposed, followed by a 
maintenance infusion and additional loading doses if necessary at certain time points.  
 
Although midazolam paediatric dosage forms are commercially available, bespoke 
reference product vials (containing midazolam) were developed to have the same 
appearance as the test product vials (containing clonidine) (Wan et al., 2013). A 
procedure has been developed so that the identity of individual study vials will remain 
unknown to the investigator, medical staff, and all subjects. All other individuals 
involved in the study (e.g. clinical study manager, medical experts and monitors) will 
also remain blinded.  
 
3.2.2 Randomisation  
Randomisation, like blinding, is fundamental to the integrity of a clinical trial. While 
it is easy to state in a funding application or even a study protocol that the study will 
be conducted in a randomised, double-blinded manner, the robust method in which 
this will be achieved in practice is often overlooked during the early phases of a trial 
(Wan et al., 2013). A centralised randomisation system is ideal for a study spanning 
multiple clinical sites, as randomisation occurs at the point of recruitment and as such, 
imbalances are minimised and it is easy to determine overall recruitment rates (Buyse, 
 8 
2000). However, such a system is expensive and needs to be investigated and 
included into the initial budget in order to be feasible. A cheaper option for 
randomisation is the generation of random numbers by a third party using a permuted 
block design. This form of randomisation is completed at the point of shipment, and 
subject kits are selected in numerical order from each clinical site (subject one 
receives kit one, subject two receives kit two, and so on). Although this is a cheaper 
procedure, it can lead to significant wastage, especially when there are multiple 
formulation strengths depending on the body weight of the patient. If the IMP is 
expensive then the cost of wastage may outweigh the cost of setting up a centralised 
system. Due to the expense of using a centralised system compared to the relatively 
low production costs of the IMP, the CloSed project has achieved randomisation by 
the generation of random numbers by a third party. A comprehensive procedure has 
been developed to ensure that the integrity of the trial remains intact. 
 
3.2.3 Preparation of patient kits 
As with many paediatric dosing regimens, selection of the appropriate formulation 
strength (low, medium or high) for the CloSed study is dependent on the body weight 
of the subject. However, in order to gain a representative sample of participants from 
preterm neonates right through to 18 year olds, the study is stratified into three age 
subsets (< 28 days, 28 days to < 2 years and ≥2 years). To maintain blinding and 
randomisation by subset, patient kits are prepared that contain enough medication to 
last the seven-day maximum trial period. The patient kit for subset 1 contains the low 
and medium formulation strengths, whereas the patient kit for subset 2 contains the 
medium and high formulations. The patient kit for subset 3 contains 14 vials of the 
high strength formulation, in case the patient weighs over 47kg and requires more 
than one vial in 24 hours. The clinician is responsible for first selecting the subject kit 
based on the age of the participant and randomisation number, then selecting the 
correct strength from within the kit based on the body weight of the patient.  
 
3.2.4 Shipment to clinical sites 
International shipment to each clinical site is an expensive and time-consuming 
process. Each site is responsible for ordering enough subject kits to last approximately 
six months, so that no more than four shipments are required to each site over the 
two-year trial period. As midazolam is a controlled drug, both an import and export 
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licence are required, specifying the quantity of midazolam. As the study kits will be 
randomised and blinded at the point of shipment, it is assumed that all vials contain 
midazolam. Temperature-controlled shipment takes place once the import and export 
licences have been processed and regulatory approval acquired. 
 
3.3 Labelling the investigational medicinal products 
As multiple countries are involved in the CloSed study, labelling of the IMPs needed 
to include multiple languages. As recruitment numbers from each site were unknown, 
it was decided to print labels as a multi-language booklet. In this way, the English 
version was on the front page, but each local language could be found by peeling open 
the booklet. The printing of labels was contracted out and guidelines were obtained 
from the printing company in the early stages of label drafting. One point to consider 
was that only the front page could be printed with variable text, therefore, the 
translated labels needed to refer to this page for medication and randomisation 
numbers. Colours were used to differentiate between the three different formulation 
strengths, with the aim of minimising dispensing errors. The selected colours were 
blue, black and orange. Red and green were intentionally excluded from the labels 
due to the high number of individuals with red-green colour blindness. 
Annex 13 (Articles 26-30) of the European Guidelines to Good Manufacturing 
Practice – Medicinal Products for Human and Veterinary Use sets out clear guidelines 
regarding the labelling of IMPs for clinical trials. However, there are country-specific 
deviations for this and these also needed consideration (Table 2). For example, the 
details of Principal Investigator are a requirement in Sweden. Labels were drafted and 
approved by representatives from all countries involved in the clinical trial. Following 
approval, the label needed to be translated into each local language. Once the labels 
were translated and merged into a single master label copy, this document had to be 
signed by each of the translators as well as the trial co-ordinator. The cycle of 
drafting, translating and approving the labels was a lengthy process that required co-
ordination between the IMP manufacturer, labelling company and representatives 
from each of the five clinical sites. 
 
Table 2 Overview of IMP label requirements, based on the European Guidelines to 
Good Manufacturing Practice – Medicinal Products for Human and Veterinary Use 
(Annex 13, Articles 26-30). 
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Packaging information  
 Study reference number  Route of administration 
 EudraCT Number  Directions for use 
 Pharmaceutical form  Quantity of dosage units 
 Subject number  Retest date 
 Vial/box number  ‘For clinical trial use only’  
 Content of vial/box  Storage instructions 
 Name, address, and telephone number 
of sponsor 
 Additional labelling according to 
local requirements 
 Name, address, and telephone number 
of the Principal Investigator  
 Other instructions/information 
 
3.4 Paediatric use marketing authorisation requirements 
The Paediatric Regulation was introduced to support the development and availability 
of paediatric medicine. It combines paediatric drug development requirements, or 
Paediatric Investigation Plans (PIPs), with incentives for the pharmaceutical industry 
to test medicines in children, such as the extension of SPC and generation of PUMA. 
Therefore, when conducting a paediatric clinical trial, a key goal should be to 
generate sufficient robust data to apply for a PUMA. This is important because even 
if, as in the CloSed study, the IMP manufacturer is different to the commercial 
manufacturer, the quality data generated needs to be sufficient not only for the clinical 
trial application and IMP Dossier (IMPD), but also for the PUMA. Although the 
production process may differ slightly between manufacturers and the IMP supplier 
may be different, meaning that not all quality data will be transferable, the generation 
of a robust set of usable data right from the early pharmaceutical development stage is 
an essential step towards a successful PUMA application.  
 
4 Summary 
The EMA has developed the Paediatric Regulation to improve the health of children 
by increasing high quality, ethical research into medicines for children. PIPs require 
careful planning and an awareness of how they will lead to a PUMA is paramount. 
However, PIP applications are often completed at an early stage, perhaps even before 
funding has been granted. A gap exists between the PIP application and the clinical 
trial phase and this is a particular challenge for publicly funded studies. Challenges 
 11 
often arise in the clinical trial phase that were not foreseen in the PIP application. By 
sharing some of the considerations and challenges encountered during the 
pharmaceutical development phase of the CloSed project, it is hoped that future 
projects will benefit in generating successful PIPs that ultimately lead to an increase 
in PUMA applications and licensed paediatric indications for new drugs.  
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